Regimen Reference Order – LYMP – R-miniCHOP

ARIA: LYMP – [R-miniCHOP]
LYMP – [R-miniCHOP (Split Day SLOW on Cycle 1)]

Planned Course: **Every 21 days for 6 cycles**
Indication for Use: **Non-Hodgkin Lymphoma**

CVAD: At Provider's Discretion (VESICANT INVOLVED)

Proceed with treatment if:
ANC equal to or greater than 0.8 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L
- **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Instruct patient to start vigorous oral pre-hydration (600-900 mL) the morning of cyclophosphamide treatment **(Self-administered at home)**		
allopurinol	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles **(Self-administered at home)** Only patients at risk of tumor lysis syndrome will be prescribed allopurinol

Treatment Regimen – LYMP – R-miniCHOP

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1		
Day 1		
predniSONE	40 mg/m^2; maximum dose 100 mg (round to nearest 5 mg)	Orally once in the morning with food **(Self-administered at home)** **predniSONE is started on Day 1** regardless if R-miniCHOP is given over one day or split over two days
cetirizine	10 mg	Orally 30 minutes prior to riTUXImab
acetaminophen	650 mg	Orally 30 minutes prior to riTUXimab
dexamethasone**	20 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medications before starting riTUXimab		

riTUXimab (IV brand name specific)	375 mg/m^2	**<u>Slow infusion</u> (if greater than 6 months since last riTUXimab dose or no previous riTUXimab):** IV made up to a final concentration of 1 mg/mL in normal saline. Start at 50 mg/hr for 60 minutes and escalate infusion rate in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr **Nursing Alert: IV tubing is primed with riTUXimab* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* **Alert: Pharmacy to ensure final volume on label* **OR** **<u>Slow infusion</u> (if equal to or less than 6 months since last riTUXimab dose):** IV made up to a final concentration of 1 mg/mL in normal saline. Start at 100 mg/hr for 30 minutes and escalate infusion rate in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr **Nursing Alert: IV tubing is primed with riTUXimab* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* **Alert: Pharmacy to ensure final volume on label*
ondansetron**	16 mg	Orally 30 minutes pre-chemotherapy
DOXOrubicin	25 mg/m^2	IV Push over 10 to 15 minutes
vinCRIStine	1 mg (flat dose)	IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion
cyclophosphamide	400 mg/m^2	IV in normal saline 250 mL over 1 hour
Days 2, 3, 4 and 5		
predniSONE	40 mg/m^2; maximum dose 100 mg (round to nearest 5 mg)	Orally once daily in the morning with food **(Self-administered at home)**
****If R-miniCHOP is split over two days, give dexamethasone 12 mg and ondansetron prior to miniCHOP on Day 2**		
Cycles 2 to 6		
Day 1		
predniSONE	40 mg/m^2; maximum dose 100 mg (round to nearest 5 mg)	Orally once in the morning with food **(Self-administered at home)**
cetirizine	10 mg	Orally 30 minutes prior to riTUXimab
acetaminophen	650 mg	Orally 30 minutes prior to riTUXimab
dexamethasone	12 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medications before starting riTUXimab		

riTUXimab (Subcutaneous)	1400 mg (1400 mg = 11.7 mL)	**Subcutaneous:** Administer over 5 minutes into abdomen Syringe should be held in hand for 5 minutes to warm up and decrease viscosity Use 25G needle *Nursing Alert: *Ensure subcutaneous riTUXimab formulation is used (riTUXimab-hyaluronidase, human)*
	OR	
riTUXimab (IV brand name specific)	375 mg/m^2	**Rapid infusion**: IV in normal saline over 90 minutes: Infuse 50 mL of a 250 mL bag (or 100 mL of a 500 mL bag) over 30 minutes, then infuse the remaining 200 mL (or 400 mL of a 500 mL bag) over 60 minutes *Alert: *Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* *Alert: *Pharmacy to ensure final volume on label*
		OR
		Slow infusion: IV made up to a final concentration of 1 mg/mL in normal saline. Start at 100 mg/hr for 30 minutes and escalate infusion rate in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr *Nursing Alert: *IV tubing is primed with riTUXimab* *Alert: *Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* *Alert: *Pharmacy to ensure final volume on label*
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
DOXOrubicin	25 mg/m^2	IV Push over 10 to 15 minutes
vinCRIStine	1 mg (flat dose)	IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion
cyclophosphamide	400 mg/m^2	IV in normal saline 250 mL over 1 hour
Days 2, 3, 4 and 5		
predniSONE	40 mg/m^2; maximum dose 100 mg (round to nearest 5 mg)	Orally once daily in the morning with food **(Self-administered at home)**
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and as clinically indicated

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

INTRAVENOUS riTUXimab

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period is required after riTUXimab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

SUBCUTANEOUS riTUXimab

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline, at discharge and as clinically indicated
- **15-minute observation period required after each dose**

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
filgrastim (brand name specific) *(See Filgrastim Clinical Guide)*	5 mcg/kg (rounded to nearest 300 mcg or 480 mcg)	Subcutaneous once daily for 5 days to start on Day 3
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Ensure patient receives filgrastim supply if patient is self-administering at home
- Instruct patient to:
  - Continue taking anti-emetic(s) at home
  - Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home
  - Empty bladder every 2 hours while awake and at bedtime for 24 hours after each dose of cyclophosphamide
  - Obtain immediate assistance as per your clinic's contact instructions if:
    - Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
    - Unable to drink recommended amount of fluid
- predniSONE is a cancer therapy in this treatment regimen. Remind patient to take predniSONE at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Cumulative DOXOrubicin dose should be calculated and should not exceed 450 mg/m^2
- Administering nurse must document any infusion-related reactions with any dose of riTUXimab
- Ensure there were **no Grade 3 or 4** infusion-related reactions with any previous dose prior to administering riTUXimab via subcutaneous injection or rapid infusion
- Intravenous riTUXimab formulation is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after riTUXimab. **Ensure prescription label matches the brand name on prescribed order for intravenous riTUXimab**